亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

A Novel Class of Exceptionally Potent HIV-1 Protease Inhibitors

總結: Researchers at Purdue University have synthesized a series of exceptionally potent inhibitors for HIV-1 protease, which have been documented as an effective strategy for the treatment of AIDS and HIV. These compounds represent a novel class of HIV-1 protease inhibitors, which have proven to be up to 20-fold more potent than other protease inhibitors on the market.

技術優勢: Far more potent than other protease inhibitors on the marketGreater potency will significantly reduce dosage requirements Treatment of multidrug-resistant strain of HIV

*Background: As reported by the World Health Organization (WHO), globally, there were 35.3 million people living with HIV/AIDS in 2012, a number that has been growing due to the increased availability of antiviral treatments. After peaking from 1997 to 2011, the incidence rate has declined nearly 30 percent from 3.5 million to 2.5 million. Within the last 10 years, the availability of antiretroviral therapy and the combination of at least three antiretroviral drugs within low- and middle-income regions has increased nearly 20-fold. In 2010, the global market for HIV/AIDS treatment was valued close to $14 billion and growing, with Gilead Sciences' market-leading protease inhibitor, Atripla, generating revenue of $3.22 billion in 2011.

*Web Links: Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry

欲了解更多信息，請點擊這裡